11:03 AM EST, 11/13/2024 (MT Newswires) -- Creative Medical Technology ( CELZ ) said Wednesday its experimental treatment for chronic lower back pain due to degenerative disc disease, CELZ-201, successfully passed an independent interim safety review by the Data Safety Monitoring Board in its clinical trial.

The clearance to proceed with the ADAPT clinical trial, which will evaluate the safety, tolerability and efficacy of CELZ-201, was granted after a safety data review from the first five dosed patients, according to the company.

The experimental drug will be administered intramuscularly and will be compared to placebo in the double-blind, dose-escalation study, Creative Medical ( CELZ ) added.

Shares of Creative Medical Technology ( CELZ ) were up 1.1% in recent trading.

Price: 2.79, Change: +0.03, Percent Change: +1.09